Moderna
Moderna, Inc., commonly referred to as Moderna, is a pioneering biotechnology company headquartered in the United States. Founded in 2010, Moderna has rapidly established itself as a leader in the mRNA technology sector, focusing on the development of transformative medicines and vaccines. The company gained global recognition for its COVID-19 vaccine, which showcased the potential of mRNA technology in combating infectious diseases. With major operational regions across North America and Europe, Moderna's core products include vaccines and therapeutics targeting infectious diseases, autoimmune disorders, and cancer. The unique aspect of Moderna's approach lies in its innovative use of messenger RNA to instruct cells to produce proteins that can prevent or treat diseases. As a key player in the biotechnology industry, Moderna continues to push the boundaries of science, achieving significant milestones and contributing to public health advancements worldwide.
DitchCarbon Score
How does Moderna's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Moderna's score of 72 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Moderna's reported carbon emissions
In 2023, Moderna reported total carbon emissions of approximately 11,240,000 kg CO2e for Scope 1 and 4,310,000 kg CO2e for Scope 2, with a total location-based Scope 2 emissions of about 11,506,000 kg CO2e. The company has set ambitious climate commitments, aiming for net-zero carbon emissions in both Scope 1 and Scope 2 by 2030. This commitment is part of a broader strategy to achieve net-zero emissions across all scopes by 2045. In 2022, Moderna's emissions included approximately 11,563,000 kg CO2e for Scope 1, 1,197,000 kg CO2e for market-based Scope 2, and a significant Scope 3 footprint of about 86,041,000 kg CO2e from capital goods alone. The company has established near-term targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 90% from a 2021 baseline by 2030. Additionally, it aims for 85% of its suppliers to have science-based targets by 2028. Moderna's long-term targets include maintaining a minimum of 90% reduction in absolute Scope 1 and 2 emissions from 2030 through 2045, alongside a 90% reduction in absolute Scope 3 emissions by 2045, all from a 2021 base year. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to sustainable practices within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 9,142,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 928,000 | 0,000,000 | 000,000 |
| Scope 3 | 489,508,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Moderna is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
